Move to topTop

TOKYO, JAPAN - July 27, 2021 - Terumo Corporation (TSE: 4543) announced today the launch of the Dexcom G6 continuous glucose monitoring (CGM) system in Japan. U.S. based Dexcom, Inc., manufactures the product, and Terumo holds the exclusive distribution agreement in Japan since their partnership in 2018.

A CGM system is a medical device that supports diabetes control. The Dexcom G6 CGM system allows real-time glucose monitoring, with its innovative technology that uses a small, wearable sensor and transmitter to measure and automatically send glucose values wirelessly to a smart device*1 or receiver every 5 minutes. Users are able to see at a glance whether they are in or out of their target glucose range. Furthermore, the system also displays trend arrows to show the speed and direction glucose levels are heading, enabling easier diabetes management decisions.

The Dexcom G6 CGM system will be the latest model of Dexcom CGM available in Japan, following the "Dexcom G4 PLATINUM system" released in 2019. Previously, measurements were sent to a dedicated receiver. With the Dexcom G6 CGM System, users can view and manage their glucose level on a smartphone application*2. With the Dexcom G6 application, users can also share their glucose information with up to 5 people, which healthcare providers can utilize during remote check-ups.

The Dexcom G6 CGM system also features customizable alerts to proactively warn users when their glucose levels are out of range and an "Urgent Low-Soon (ULS) Alert" that can warn users 20 minutes in advance of a severe hypoglycemic event, giving them time to take appropriate action.

Diabetes is a complex and chronic disease, which may lead to complications such as: blindness, neuropathy, kidney disease, myocardial infarction or stroke. To avoid aggravation and avoid onset of complications, it is important for patients to control their glucose levels day-to-day. Yoshiya Kikawa, general manager, DM and Consumer Healthcare Group of Terumo commented, "The launch of Dexcom G6 CGM System in Japan is an important milestone for Terumo as we promise to commit to contribute to diabetes care comprehensively. With our vivid product lineup of CGM, blood glucose system, and Japan's first tubing-free insulin patch pump, we will continue to strive to improve the Quality of life for people living with diabetes".

  • 20210727-1.png

    Dexcom G6 CGM System consists of 3 components

    ●Applicator with built-in sensor


    ●Display device (Smart device*1 or Dedicated receiver)

  • 20210727-2.jpg

    Sensor and transmitter placed on a user

  • *1

    The smart device is not included the system.

  • *2

    There is limitation on smartphone device compatibility.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.